
<http://bio2rdf.org/drugbank:DB00043> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Omalizumab" ;
	<http://schema.org/description> "A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin." ;
	<http://schema.org/drugClass> "Immunosuppressive Agents" , "Anti-Allergic Agents" , "Anti-Asthmatic Agents" ;
	<http://schema.org/url> "http://bio2rdf.org/drugbank:DB00043" ;
	<http://schema.org/administrationRoute> "subcutaneous" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:0fcaf4f0483004d12409b1ad95c0e879> , <http://bio2rdf.org/drugbank_resource:fe40d51468a18c08bc4fff82c5a509d0> ;
	<http://schema.org/clinicalPharmacology> "Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:212c074bcfde9c3dad8650d8434f1d92> ;
	<http://schema.org/dosageForm> "Injection, solution" , "Powder for solution" ;
	<http://schema.org/interactingDrug> "DDI between Omalizumab and Loxapine - Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine." , "DDI between Omalizumab and Belimumab - Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab." ;
	<http://schema.org/legalStatus> "Approved" , "Investigational" ;
	<http://schema.org/mechanismOfAction> "Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils." ;
	<http://schema.org/nonProprietaryName> "Ig gamma-1 chain C region" ;
	<http://schema.org/identifier> "drugbank:DB00043" ;
	<http://schema.org/sameAs> <http://www.rxlist.com/cgi/generic/xolair.htm> , <http://www.drugbank.ca/drugs/DB00043> , <http://www.drugs.com/cdi/omalizumab.html> .

<http://bio2rdf.org/drugbank_resource:0fcaf4f0483004d12409b1ad95c0e879> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "202.5 mg/1.4mL Injection, solution form with subcutaneous route" .

<http://bio2rdf.org/drugbank_resource:212c074bcfde9c3dad8650d8434f1d92> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "715.41998291015625" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Xolair 150 mg vial" .

<http://bio2rdf.org/drugbank_resource:fe40d51468a18c08bc4fff82c5a509d0> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "150 mg Powder for solution form with subcutaneous route" .
